Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?;Verbessert die individuelle bestimmung der effektiven halbwertszeit die ergebnisse der radioiodtherapie des Morbus basedow?

NuklearMedizin

Volumn 41, Issue 6, 2002, Pages 240-244

  Schneider, Peter ^a   Korber C ^a   Korber Hafner N ^a   Hanscheid H ^a   Reiners, Chr ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dosimetry; Graves' disease; Radioiodine therapy; Specific dose

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE; THYROTROPIN;

ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG HALF LIFE; DRUG WITHDRAWAL; EUTHYROIDISM; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; RADIOISOTOPE THERAPY; THYROID TUMOR; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0036928482     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625295     Document Type: Article

References (20)

1. Alexander EK, Larsen P, Reed H. High dose I-131 therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87: 1073-7.
2. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 4012-6.
3. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993; 34: 1632-8.
4. Brage M, Walpert N, Burch HB, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: A randomized clinical trial. Thyroid 2002; 12: 135-9.
5. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetrie der Schilddrüsenlappen mittels Real-time-Sonographie. Dtsch Med Wschr 1981; 106: 1338-40.
6. Dietlein M, Dressler J, Joseph K, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O. Leitlinie zur Radioiodtherapie benigner Schilddrüsenerkrankungen, Nuklearmedizin 1999; 38: 19-20.
7. Körber C, Schneider P, Hänscheid H, Köck PR, Reiners C. Reliability of posttherapeutic dosimetry of patients with short-time hospitalisation after radioiodine therapy. Nuklearmedizin 2000; 39: 1-4.
8. Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goiter? Eur J Nucl Med 2001; 28: 1360-4.
9. Körber C, Schneider P, Hänscheid H, Köck PR, Reiners C. Reliability of posttherapeutic dosimetry of patients with short-time hospitalisation after radioiodine therapy. Nuklearmedizin 2000; 39: 1-4.
10. Meier DA, Brill DR, Becker DV, Clarke SEM, Silberstein EB, Royal HD, Balon HR. Procedure guideline for therapy of thyroid disease with I-131. J Nucl Med 2002; 43: 856-61.
11. Moka D, Voth E, Schicha H. Einfluß von thyreostatischer Medikation auf die effektive Halbwertszeit und Uptake von 131-Iod während der Radioiodtherapie. Nuklearmedizin 1997; 30: 87-92.
12. Moka D, Schicha H, Körber C, Schneider P, Reiners C. Reduced antithyroid agents as a result of radioiodine therapy? Nuklearmedizin 2000; 39: N25-6.
13. 131iodine activity. Results from a prospective, randomized multicenter study. Eur J Clin Invest 1995; 25: 186-93.
14. Reiners C. Radioiodtherapie des Morbus Basedow. Z Ärztl Fortbild Qual 1999; 93 (Suppl.): 1-6.
15. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Büll U. Radioiodine therapy in Graves' disease with large diffuse goiter with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9: 1181-8.
16. Sabri O, Schluz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohmen BM, Bares R, Büll U. Bestimmung der Einflussfaktoren für den Therapieerfolg der Radioiodtherapie bei Patienten mit Morbus Basedow. Nuklearmedizin 1998; 37: 83-9.
17. Schicha H, Eschner W. Die neue Strahlenschutzverordnung aus der Sicht des Nuklearmediziners an der Klinik. Der Nuklearmedizinet 2002; 25: 10-4.
18. Tuttle RM, Patience T, Budd S. Treatment with propycilthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995; 5: 243-7.
19. Urbannek V, Voth E, Moka D, Schicha H. Radioiodtherapie des Morbus Basedow dosimetrischer Vergleich verschiedener Therapieregime bezüglich der Thyreostatikagabe. Nuklearmedizin 2001; 40: 111-5.
20. Van Isselt JW, de Klerk JM, Koppeschaar HP, Van Rijk PP. Iodine-131 uptake and turnover rate vary over short interval in Graves' disease. Nucl Med Commun 2000; 21: 609-16.